Skip to main content
Signal8

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

$INCYPress releaseJul 13, 2026, 4:00 AM ETRead the release

Incyte presented Phase 1/2 data for VGA039 (latarcibart) showing an 81% median reduction in annualized bleeding rates across all von Willebrand disease types. The subcutaneous therapy was safe and well tolerated over multiple doses, with patients switching from IV prophylaxis experiencing bleed reductions of 75-100%.

Key figures

Drug Name
VGA039 (Latarcibart)
Phase Of Trial
Phase 1/2
Abr reduction
81% median reduction
Patient count
16
Prior prophylaxis reduction
75-100%
Breakthrough bleed reduction
~86%

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    INCY: Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types — AI Analysis | Signal8